Nasal Drug Delivery CDMO Market Size, Share, Scope, Forecast Report 2026 to 2035

What is Nasal Drug Delivery CDMO Market Size?

Global Nasal Drug Delivery CDMO Market Size is predicted to grow at a 10.5% CAGR during the forecast period for 2026 to 2035.

Nasal Drug Delivery CDMO Market Size, Share & Trends Analysis Distribution by Service Type (Formulation & Feasibility, Analytical & Nasal-Spray Characterization, Device & Drug-Device Integration, Clinical Trial Manufacturing (Phase I–III), Commercial Manufacturing (Fill-Finish & Device Assembly), Packaging & Serialization, Regulatory / CMC / Lifecycle, by Dosage Form (Unit-Dose Spray, Bi-Dose Spray, Multi-Dose Metered Spray, Nasal Powder / Dry-Powder, Nasal Drops & Liquids, Nasal Gels & Semi-Solids), by Molecule Class (Small Molecules, Peptides, Proteins & Antibodies, Vaccine Antigens, Nucleic Acids (mRNA / Oligonucleotides), by Application (Allergic Rhinitis & ENT, Migraine & Headache, Emergency & Rescue, CNS / Neurology / Nose-to-Brain, Pain Management, Vaccines & Mucosal Immunization, Hormonal & Endocrine, Anti-Infective & Other), by Customer Type, by Development Phase and Segment Forecasts, 2026 to 2035,

Nasal drug delivery means giving medicines through the nose to treat local issues, reach the whole body, or target the brain directly. In recent years, this method has grown from just allergy and decongestant products to a platform capable of handling complex biologics, emergency treatments, vaccines, peptides, central nervous system drugs, and fast-acting therapies. Using the nasal route offers several key benefits, including rapid absorption, non-invasive administration, greater patient convenience, avoidance of first-pass metabolism, and the ability to deliver drugs directly to the brain. As drug companies seek more patient-friendly, fast-acting treatments, nasal drug delivery is becoming increasingly important across many areas. The market for nasal drug delivery CDMOs is growing quickly as more pharmaceutical and biotech companies choose to outsource tasks like formulation development, testing, device integration, manufacturing, and regulatory support to specialized partners. Making nasal drug-device products requires specialised skills in formulation, spray testing, device matching, particle engineering, sterility, and regulatory compliance. Because of this, many drug makers work with experienced CDMOs to accelerate development, streamline operations, and scale up manufacturing.

The need for fast-acting, non-invasive treatments is driving market growth. More often, intranasal delivery is used for migraines, seizure rescue, reversing opioid overdoses, pain relief, allergies, hormone therapies, and emergency care because it works quickly and is easy to use. There is also more research into delivering drugs from the nose to the brain for conditions like Parkinson’s, Alzheimer’s, epilepsy, depression, and other brain disorders. This is opening up new opportunities for specialized nasal drug delivery platforms and CDMO services. Another major trend shaping the market is the growing development of biologics, peptides, proteins, vaccines, and nucleic acid-based therapies for intranasal administration.

Pharmaceutical companies are exploring. Another key trend is the rise of biologics, peptides, proteins, vaccines, and nucleic acid therapies for nasal delivery. Drug companies see nasal delivery as a good option for mucosal immunization, needle-free vaccines, and targeted brain treatments. This is driving demand for advanced formulation methods, powder technology, preservative-free systems, nanoparticle delivery, and better device integration. CDMOs are investing in testing platforms, nasal spray analysis, sterile manufacturing, and automated filling to handle more complex products.h-powered devices, and dry-powder nasal platforms are improving dosing accuracy, ease of use, portability, and patient compliance. Regulatory agencies are placing greater emphasis on human factor engineering, device performance validation, and product consistency, encouraging pharmaceutical companies to work with CDMOs that offer integrated drug-device development expertise.

Technological advancements in spray characterisation, droplet analysis, particle deposition modelling, device engineering, and aseptic manufacturing are further improving product performance. New technologies in spray testing, droplet analysis, particle modelling, device design, and sterile manufacturing are making products work better and manufacturing more efficient. CDMOs are using more automated filling, digital quality checks, advanced labs, and scalable production to keep up with global demand. Partnerships between drug companies, device makers, and specialised CDMOs are also accelerating innovation and bringing new nasal drug-delivery products to market.Even with strong growth, the market still faces challenges.

Nasal drug products often need complex formulations, must meet strict regulations, and require careful device matching and testing. It can be hard to get consistent spray performance, dose accuracy, stability, and bioavailability, especially for biologics, peptides, and drugs targeting the brain. High development costs, changing regulations, and the need for special manufacturing setups can also make it hard for some companies to enter the market. Still, ongoing progress in drug-device combinations, biologic drugs, nose-to-brain treatments, and emergency medicines should help the market grow over time. As drug companies focus more on fast delivery, patient convenience, targeted treatments, and non-invasive options, nasal drug delivery CDMOs will continue to play a key role in developing, manufacturing, and launching new intranasal therapies worldwide.

Competitive Landscape

Which are the Leading Players in the Nasal Drug Delivery CDMO Market?

• Kindeva Drug Delivery
• Summit Biosciences
• Bespak
• Catalent
• LTS Lohmann Therapie-Systeme
• Renaissance Lakewood
• Recipharm
• Unither Pharmaceuticals
• Grünenthal PRO
• Delpharm
• Aptar Pharma
• Lonza
• Hovione
• Biodeal Pharmaceuticals
• Aurigene Pharmaceutical Services
• Douglas CDMO

Market Dynamics

Driver

Growing Demand for Rapid-Acting and Non-Invasive Drug Delivery Solutions

A key driver of the nasal drug delivery CDMO Market is the rising demand for fast-acting, non-invasive drug delivery systems across many therapeutic areas. Nasal drug delivery offers several benefits, including rapid absorption, ease of use, improved patient comfort, and avoidance of first-pass metabolism. These advantages make it a good choice for emergency treatments, migraines, CNS disorders, pain relief, and hormone therapies. There is also more research into nose-to-brain drug delivery for neurological conditions like Parkinson’s disease, epilepsy, and Alzheimer’s disease, which is boosting interest in advanced nasal formulations. As a result, pharmaceutical and biotech companies are working more closely with specialised CDMOs to support formulation, device integration, testing, and large-scale production of complex nasal drug products.

Restrain/Challenge

Complex Regulatory Requirements and Technical Development Challenges

A major challenge in the nasal drug delivery CDMO Market is the technical complexity and strict regulations for nasal drug-device combination products. Nasal formulations require careful control of spray performance, droplet size, dose consistency, stability, sterility, and device fit to ensure they are safe and effective. Regulators require detailed testing, human factor studies, and device checks, which makes development slow and costly. Developing biologics, peptides, and nose-to-brain therapies for nasal delivery is also difficult due to stability and bioavailability issues. CDMOs need to keep investing in advanced testing tools, specialised manufacturing, and regulatory know-how to keep up with industry standards and client needs.
Commercial Manufacturing (Fill-Finish & Device Assembly) Segment is Expected to Drive the Nasal Drug Delivery CDMO Market
The nasal drug delivery CDMO market will be driven by the Commercial Manufacturing segment. This segment includes activities such as fill-finish and device assembly. The reason for this is that more and more nasal sprays and other products are being sold in the market. As new treatments for things like allergies and migraines become available big pharmaceutical companies are looking for help with making these products on a scale. The Nasal Drug Delivery CDMO Market is where they go for this help. To make these products, you need specialised equipment and careful checks to ensure they are safe. There is also a growing need for preservative-free products and devices that can deliver the medicine dose. Because of this companies are investing in ways to make these products. The Nasal Drug Delivery CDMO Market helps pharmaceutical companies develop their products more efficiently and at lower cost.

Multi-Dose Metered Spray Segment is Expected to Drive the Nasal Drug Delivery CDMO Market

The nasal drug delivery CDMO market will also be driven by the Multi-Dose Metered Spray segment. This segment is important because it is used for both term and long-term treatments. People like these sprays because they are easy to use and deliver the medicine dose. The Nasal Drug Delivery CDMO Market is used to treat a lot of things like allergies and migraines. Pharmaceutical companies want to make it easier for patients to take their medicine so they are looking for better ways to do this. The Nasal Drug Delivery CDMO Market is helping make this happen by working with device manufacturers and pharmaceutical companies to ensure products work well and are manufactured at scale. The Multi-Dose Metered Spray segment is growing due to technologies such as breath-powered devices and preservative-free systems. The Nasal Drug Delivery CDMO Market is expected to continue growing as pharmaceutical companies partner with Nasal Drug Delivery CDMOs to develop better products.

Why North America Led the  Nasal Drug Delivery CDMO Market?

North America leads the nasal drug delivery CDMO market thanks to its strong pharmaceutical and biotech sectors, advanced healthcare systems, and focus on new drug-delivery technologies. The United States is especially important, as it hosts many top pharmaceutical companies, biotech firms, CDMOs, and nasal drug-device developers. Demand for intranasal therapies is rising in areas like allergic rhinitis, migraine treatment, emergency rescue medicines, CNS disorders, pain management, and vaccines. North America’s leadership is also driven by more investment in biologics, peptide-based drugs, and nose-to-brain therapies. Companies in the region are developing advanced nasal formulations that provide fast drug absorption, greater patient convenience, and non-invasive use. More people are also learning about emergency rescue nasal sprays, like those for opioid overdose and seizures, which is boosting demand for nasal drug delivery products. Advanced manufacturing facilities and strong regulatory know-how also make the

North American market stronger. CDMOs in the region are investing in formulation development, analytical testing, spray technology, aseptic fill-finish systems, and device integration to support more complex nasal drug-device products. Partnerships between pharmaceutical companies, biotech firms, and device makers are speeding up innovation and bringing new products to market faster. Government support for pharmaceutical innovation, more clinical research, and higher healthcare spending are also helping the market grow. More companies are investing in intranasal therapies as patient-friendly, fast-acting drug delivery systems become more popular. Thanks to strong research, advanced manufacturing, and rising demand for new nasal drug delivery solutions, North America remains the leader in the global Nasal Drug Delivery CDMO Market.

Key Developments:

•    In January 2026, Summit Biosciences strengthened its sterile nasal spray manufacturing infrastructure by enhancing analytical testing, formulation development, and commercial-scale fill-finish services for pharmaceutical partners.

•    In January 2026, Unither Pharmaceuticals strengthened sterile blow-fill-seal manufacturing capabilities for nasal drug products to support high-volume pharmaceutical outsourcing requirements.

Nasal Drug Delivery CDMO Market Report Scope :